The expanding repertoire of AKI biomarkers offers opportunities for early detection, risk stratification, and physiological understanding of perioperative kidney injury, with regulatory-approved markers NGAL and TIMP-2*IGFBP-7, along with emerging candidates like CCL-14 or PENK demonstrating clinical utility when integrated into structured care bundles. The gene discussed is TIMP2; the disease is acute kidney injury.